Harrow Acquires TYRVAYA Rights from Viatris to Expand Ophthalmology Portfolio

Key Facts

In a move reflecting strategic expansion within the specialized healthcare sector, Harrow has announced a definitive agreement to acquire the global rights for TYRVAYA from Viatris Inc. This nasal spray is the first FDA-approved cholinergic agonist treatment for dry eye disease. The acquisition aims to broaden Harrow's portfolio of ophthalmic disease management solutions by integrating a unique asset already approved in major global markets, including the United States and China.

Under the terms of the agreement, Harrow will pay $30 million in cash at closing, with additional contingent milestone payments tied to net sales of up to $70 million, bringing the potential total consideration to $100 million. Per market data and financial reports, this transaction exemplifies a disciplined approach to capital allocation. The addition of TYRVAYA, which demonstrated efficacy in clinical trials involving hundreds of subjects, is expected to strengthen the company's revenue base within the ophthalmology market.

Looking ahead, while updated price levels for HROW were unavailable at the close of August 6, 2026, the outlook remains positive due to the strategic asset integration. Investors will be watching for the formal closing of the deal and its impact on upcoming earnings reports. Meanwhile, broader market sentiment may be influenced by upcoming global economic catalysts, such as Manufacturing PMI data from China and Europe, which often impact risk appetite in the pharmaceutical sector.